Viewing Study NCT06082102


Ignite Creation Date: 2025-12-25 @ 3:52 AM
Ignite Modification Date: 2025-12-26 @ 2:41 AM
Study NCT ID: NCT06082102
Status: RECRUITING
Last Update Posted: 2025-09-15
First Post: 2023-10-08
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module